Breaking Finance News

ValuEngine upgraded Infinity Pharmaceuticals Inc. (NASDAQ:INFI) to Hold in a report released today.

Yesterday Infinity Pharmaceuticals Inc. (NASDAQ:INFI) traded -2.56% lower at $1.56. The company’s 50-day moving average is $1.44 and its 200-day moving average is $2.09. The last closing price is down -45.39% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time period. 627,359 shares of the stock traded hands, up from an average trading volume of 435,569

ValuEngine has upgraded Infinity Pharmaceuticals Inc. (NASDAQ:INFI) to Hold in a report released on 07/06/2017.

See Chart Below

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals Inc. has a 52 week low of $0.84 and a 52 week high of $3.84 The company’s market cap is currently $0.

In addition to ValuEngine reporting its stock price target, a total of 8 brokers have issued a research note on the company. The average stock price target is $13.50 with 4 brokers rating the stock a strong buy, 4 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.